Dr. Reid Robison, Chief Clinical Officer at Numinus, joins Paul F. Austin to discuss psychedelic research, legislation, & complementary modalities.

Find episode links, summary, and transcript here.

Dr. Robison shares the challenges and innovations in psychedelic therapy, drawing from his own clinical research and current projects at Numinus, a mental health company that brings safe, evidence-based psychedelic-assisted therapies to people in need. Explore topics such as the efficacy of psychedelic-assisted therapies, the pros and cons of psychedelic patents, and the need for multimodal approaches to mental health care.

Dr. Reid Robison is a board-certified psychiatrist and Chief Clinical Officer at Numinus, where he oversees clinical services, including teaching and training in ketamine-assisted psychotherapy, for the company's clinics across the US and Canada. He has led over 200 clinical trials in neuropsychiatry and previously served as coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders.

Dr. Robison is currently principal investigator for a number of psychedelic medicine studies with psilocybin, LSD, and DMT. As a researcher and early adopter of ketamine in psychiatry, Dr. Robison got his first grant to study that medicine in 2011, around which time he also led a pivotal IV ketamine study for treatment-resistant depression.

To date, Dr. Robison has guided thousands of ketamine therapy journeys and Spravato dosing sessions, and has also worked in ayahuasca retreat settings abroad. Dr. Robison is an adjunct professor at both the University of Utah and Brigham Young University, and board chair of the Psychedelic Institute, focused on education and research.

Highlights:

• Dr. Robison's journey into the world of psychedelics, from ketamine research to psilocybin advocacy on Capitol Hill.
• How patents can expand access to psychedelic therapy through health insurance.
• Dr. Robison’s innovative studies and projects at Numinus.
• The need for a new standard of mental health care and the role of complementary modalities in achieving it.
• Exploring modalities complementary to psychedelic therapy.
• The promise of personalized mental health care.
• The pioneering efforts of Numinus in offering employee psychedelic mental health care via ketamine. 
• The future of insurance and the potential for greater coverage of ketamine-assisted psychotherapy.
• What’s on the horizon at Numinus.

Key Links:

• Dr. Robison’s Website
• Numinus

Episode Sponsors:

• Numinus
• Third Wave's Mushroom Grow Kit